Cardiovascular insufficiency, abdominal sepsis, and patients' age are associated with decreased paraoxonase-1 (PON1) activity in critically ill patients with Multiple Organ Dysfunction Syndrome (MODS)

Disease Markers

Volumn 2019, Issue , 2019, Pages

  Bednarz Misa, Iwona ^a   Mierzchala Pasierb, Magdalena ^a   Lesnik, Patrycja ^a   Placzkowska, Sylwia ^a   Kedzior, Krzysztof ^a   Gamian, Andrzej ^a,b   Krzystek Korpacka, Malgorzata ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; C REACTIVE PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE BINDING PROTEIN; PROCALCITONIN; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; PON1 PROTEIN, HUMAN;

ABDOMINAL INFECTION; ACCURACY; ADULT; AGE; AGED; APACHE; ARTICLE; BLOODSTREAM INFECTION; BODY TEMPERATURE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; ADOLESCENT; BLOOD; MIDDLE AGED;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ARYLDIALKYLPHOSPHATASE; BIOMARKERS; CARDIOVASCULAR DISEASES; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; SHOCK, SEPTIC;

EID: 85062273443     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2019/1314623     Document Type: Article

References (42)

1. S. S. Avad and S. C. Gale, "Multiple organ dysfunction syndrome: Pathogenesis, management, and prevention, " in Preoperative Care of the Surgical Patient, J. E. Fisher, Ed., pp. 110-125, Lippincott Williams & Wilkins, Philadelphia, PA, USA, 2007.
2. S. V. Baudouin, "Sepsis: Introduction and epidemiology, " in Sepsis, S. V. Baudouin, Ed., pp. 1-4, Springer-Verlag London Limited, 2008.
3. C. A. Prauchner, "Oxidative stress in sepsis: Pathophysiological implications justifying antioxidant co-therapy, " Burns, vol. 43, no. 3, pp. 471-485, 2017.
4. A. Kübler, G. Durek, A. Zamirowska et al., "Ciȩzka sepsa w Polsce - wyniki internetowej rejestracji 1043 przypadków (sever sepsis in Poland - results from web registration of 1043 cases), " Medical Science Monitor, vol. 10, no. 11, pp. -CR635-CR641, 2004.
5. R. W. James, "A long and winding road: Defining the biological role and clinical importance of paraoxonases, " Clinical Chemistry and Laboratory Medicine, vol. 44, no. 9, pp. 1052-1059, 2006.
6. D. I. Draganov, J. F. Teiber, A. Speelman, Y. Osawa, R. Sunahara, and B. N. La Du, "Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities, " Journal of Lipid Research, vol. 46, no. 6, pp. 1239-1247, 2005.
7. L. Rothem, C. Hartman, A. Dahan, J. Lachter, R. Eliakim, and R. Shamir, "Paraoxonases are associated with intestinal inflammatory diseases and intracellularly localized to the endoplasmic reticulum, " Free Radical Biology & Medicine, vol. 43, no. 5, pp. 730-739, 2007.
8. O. Khersonsky and D. S. Tawfik, "Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase, " Biochemistry, vol. 44, no. 16, pp. 6371-6382, 2005.
9. Y. H. Dong and L. H. Zhang, "Quorum sensing and quorum-quenching enzymes, " The Journal of Microbiology, vol. 43, pp. 101-109, 2005.
10. B. Bedi, Z. Yuan, M. Joo et al., "Enhanced clearance of Pseudomonas aeruginosa by peroxisome proliferator-activated receptor gamma, " Infection and Immunity, vol. 84, no. 7, pp. 1975-1985, 2016.
11. K. Kowalska, E. Socha, and H. Milnerowicz, "Review: The role of paraoxonase in cardiovascular diseases, " Annals of Clinical and Laboratory Science, vol. 45, no. 2, pp. 226-233, 2015.
12. J. Camps, S. Iftimie, A. García-Heredia, A. Castro, and J. Joven, "Paraoxonases and infectious diseases, " Clinical Biochemistry, vol. 50, no. 13-14, pp. 804-811, 2017.
13. D. Boehm, M. Krzystek-Korpacka, K. Neubauer et al., "Paraoxonase-1 status in Crohn's disease and ulcerative colitis, " Inflammatory Bowel Diseases, vol. 15, no. 1, pp. 93-99, 2009.
14. M. Krzystek-Korpacka, D. Boehm, M. Matusiewicz, D. Diakowska, K. Grabowski, and A. Gamian, "Paraoxonase 1 (PON1) status in gastroesophageal malignancies and associated paraneoplastic syndromes - connection with inflammation, " Clinical Biochemistry, vol. 41, no. 10-11, pp. 804-811, 2008.
15. M. Krzystek-Korpacka, E. Patryn, K. Hotowy et al., "Paraoxonase (PON)-1 activity in overweight and obese children and adolescents: Association with obesity-related inflammation and oxidative stress, " Advances in Clinical and Experimental Medicine, vol. 22, no. 2, pp. 229-236, 2013.
16. F. Novak, L. Vavrova, J. Kodydkova et al., "Decreased paraoxonase activity in critically ill patients with sepsis, " Clinical and Experimental Medicine, vol. 10, no. 1, pp. 21-25, 2010.
17. D. Draganov, J. Teiber, C. Watson et al., "PON1 and oxidative stress in human sepsis and an animal model of sepsis, " Advances in Experimental Medicine and Biology, vol. 660, pp. 89-97, 2010.
18. Y. Li, R. Zhai, H. Li, X. Mei, and G. Qiu, "Prognostic value of serum paraoxonase and arylesterase activity in patients with sepsis, " The Journal of International Medical Research, vol. 41, no. 3, pp. 681-687, 2013.
19. S. Bojic, J. Kotur-Stevuljevic, N. Kalezic et al., "Low paraoxonase 1 activity predicts mortality in surgical patients with sepsis, " Disease Markers, vol. 2014, Article ID 427378, 8 pages, 2014.
20. V. Inal, L. Yamanel, G. Taşkin, S. Tapan, and B. Cömert, "Paraoxonase 1 activity and survival in sepsis patients, " Balkan Medical Journal, vol. 32, no. 2, pp. 183-188, 2015.
21. G. Ayar, Y. M. Atmaca, M. Alişik, and Ö. Erel, "Effects of paraoxonase, arylesterase, ceruloplasmin, catalase, and myeloperoxidase activities on prognosis in pediatric patients with sepsis, " Clinical Biochemistry, vol. 50, no. 7-8, pp. 414-417, 2017.
22. A. Annagür, R. Örs, H. Altunhan et al., "Total antioxidant and total oxidant states, and serum paraoxonase-1 in neonatal sepsis, " Pediatrics International, vol. 57, no. 4, pp. 608-613, 2015.
23. X. Schmit and J. L. Vincent, "The time course of blood C-reactive protein concentrations in relation to the response to initial antimicrobial therapy in patients with sepsis, " Infection, vol. 36, no. 3, pp. 213-219, 2008.
24. T. Mauri, G. Bellani, N. Patroniti et al., "Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality, " Intensive Care Medicine, vol. 36, no. 4, pp. 621-629, 2010.
25. M. Mierzchala, M. Krzystek-Korpacka, A. Gamian, and G. Durek, "Quantitative indices of dynamics in concentrations of lipopolysaccharide-binding protein (LBP) as prognostic factors in severe sepsis/septic shock patients - comparison with CRP and procalcitonin, " Clinical Biochemistry, vol. 44, no. 5-6, pp. 357-363, 2011.
26. M. Krzystek-Korpacka, M. Mierzchala, K. Neubauer, G. Durek, and A. Gamian, "Midkine, a multifunctional cytokine, in patients with severe sepsis and septic shock: A pilot study, " Shock, vol. 35, no. 5, pp. 471-477, 2011.
27. R. C. Bone, R. A. Balk, F. B. Cerra et al., "American College of Chest Physicians /Society of Critical Care Medicine Consensus Conference Committee: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis, " Critical Care Medicine, vol. 20, no. 6, pp. 864-874, 1992.
28. R. C. Bone, R. A. Balk, F. B. Cerra et al., "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/ Society of Critical Care Medicine, " Chest, vol. 101, no. 6, pp. 1644-1655, 1992.
29. J.-L. Vincent, R. Moreno, J. Takala et al., "The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/ failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine, " Intensive Care Medicine, vol. 22, no. 7, pp. 707-710, 1996.
30. W. A. Knaus, E. A. Draper, D. P. Wagner, and J. E. Zimmerman, "APACHE II: A severity of disease classification system, " Critical Care Medicine, vol. 13, no. 10, pp. 818-829, 1985.
31. B. N. La Du, S. Billecke, C. Hsu, R. W. Haley, and C. A. Broomfield, "Serum paraoxonase (PON1) isozymes: The quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals, " Drug Metabolism and Disposition, vol. 29, 4 Part 2, pp. 566-569, 2001.
32. V. Bewick, L. Cheek, and J. Ball, "Statistics review 13: Receiver operating characteristic curves, " Critical Care, vol. 8, no. 6, pp. 508-512, 2004.
33. T. S. R. van Engelen, W. J. Wiersinga, B. P. Scicluna, and T. van der Poll, "Biomarkers in sepsis, " Critical Care Clinics, vol. 34, no. 1, pp. 139-152, 2018.
34. L. E. White, R. Chaudhary, L. J. Moore, F. A. Moore, and H. T. Hassoun, "Surgical sepsis and organ crosstalk: The role of the kidney, " The Journal of Surgical Research, vol. 167, no. 2, pp. 306-315, 2011.
35. D. Limongi, C. D'Agostini, and M. Ciotti, "New sepsis biomarkers, " Asian Pacific Journal of Tropical Biomedicine, vol. 6, no. 6, pp. 516-519, 2016.
36. W. H. W. Tang, J. Hartiala, Y. Fan et al., "Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 11, pp. 2803-2812, 2012.
37. D. C. Lee, H. A. Sohn, Z. Y. Park et al., "A lactate-induced response to hypoxia, " Cell, vol. 161, no. 3, pp. 595-609, 2015.
38. A. Gugliucci, K. Kotani, and S. Kimura, "Paraoxonase 1 in chronic kidney failure, " Journal of Lipids, vol. 2012, Article ID 726048, 10 pages, 2012.
39. L. G. Costa, A. Vitalone, T. B. Cole, and C. E. Furlong, "Modulation of paraoxonase (PON1) activity, " Biochemical Pharmacology, vol. 69, no. 4, pp. 541-550, 2005.
40. Y. Y. Sautin and R. J. Johnson, "Uric acid: The oxidant-antioxidant paradox, " Nucleosides, Nucleotides & Nucleic Acids, vol. 27, no. 6-7, pp. 608-619, 2008.
41. R. J. Johnson, T. Nakagawa, D. Jalal, L. G. Sánchez-Lozada, D. H. Kang, and E. Ritz, "Uric acid and chronic kidney disease: which is chasing which?, " Nephrology, Dialysis, Transplantation, vol. 28, no. 9, pp. 2221-2228, 2013.
42. G. Iapichino, M. Umbrello, M. Albicini et al., "Time course of endogenous nitric oxide inhibitors in severe sepsis in humans, " Minerva Anestesiologica, vol. 76, no. 5, pp. 325-333, 2010.